Drugs / JK08
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05620134 | Oct 2022 → Oct 2025 overdue | clear cell renal carcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, gastroesophageal cancer +13 | Salubris Biotherapeutics Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-10-24 | Salubris Biotherapeutics Inc | Results Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023 salubrisbio.com ↗
At the dose levels evaluated to date, JK08 has been well tolerated, demonstrating preliminary disease stability and anticipated modulation of target immune cell populations in heavily pre-treated patients. |
| 2023-03-28 | Salubris Biotherapeutics Inc | Results Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates salubrisbio.com ↗
Favorable Pharmacodynamic Activities Observed Across Cohorts |
| 2023-01-03 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Regulatory 用于治疗晚期实体瘤的SAL008注射液在国内获批临床 salubris.com ↗
近日，信立泰创新抗肿瘤生物药SAL008注射液获得国家药品监督管理局批准，同意开展晚期实体瘤适应症Ⅰ期临床试验。 |
| 2022-10-10 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Regulatory SAL008注射液国内临床试验申请获受理 salubris.com ↗
其自主研发、具有知识产权的创新抗肿瘤生物药（first-in-class）SAL008注射液临床试验申请获得受理。 |
| 2022-09-29 | Salubris Biotherapeutics Inc | Regulatory Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction salubrisbio.com ↗
Company also Announces the First CTA Approval for JK08, the First Investigational IL15-CTLA4 Antibody Fusion for Solid Tumors |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-24 | Salubris Biotherapeutics Inc | Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023 salubrisbio.com ↗ |
| 2023-03-28 | Salubris Biotherapeutics Inc | Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates salubrisbio.com ↗ |
| 2023-01-03 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 用于治疗晚期实体瘤的SAL008注射液在国内获批临床 salubris.com ↗ |
| 2022-10-10 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | SAL008注射液国内临床试验申请获受理 salubris.com ↗ |
| 2022-09-29 | Salubris Biotherapeutics Inc | Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction salubrisbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JK08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05620134 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant fusion protein consisting of two functional elements” NCT05620134 ↗ |
| Route | Subcutaneous | “subcutaneously administered JK08” NCT05620134 ↗ |
| Target | CTLA4 | “directed against CTLA-4” NCT05620134 ↗ |